Palmitoylethanolamide sold as Levagen + — Competitive Intelligence Brief

Palmitoylethanolamide sold as Levagen + (Palmitoylethanolamide sold as Levagen +) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PPAR-α agonist; endogenous lipid mediator. Area: Pain management; Neurology.

phase 3 PPAR-α agonist; endogenous lipid mediator PPAR-α (peroxisome proliferator-activated receptor alpha) Pain management; Neurology Small molecule

Target snapshot

Palmitoylethanolamide sold as Levagen + (Palmitoylethanolamide sold as Levagen +) — RDC Clinical Pty Ltd. Palmitoylethanolamide is an endogenous fatty acid amide that modulates pain and inflammation by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and reducing neuroinflammation.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Palmitoylethanolamide sold as Levagen + TARGET	Palmitoylethanolamide sold as Levagen +	RDC Clinical Pty Ltd	phase 3	PPAR-α agonist; endogenous lipid mediator	PPAR-α (peroxisome proliferator-activated receptor alpha)
ultra-micronized palmitoylethanolamide	ultra-micronized palmitoylethanolamide	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Endocannabinoid-like lipid mediator / PPAR-α agonist	PPAR-α; mast cell stabilization

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PPAR-α agonist; endogenous lipid mediator class)

1. RDC Clinical Pty Ltd · 1 drug in this class